Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Cash & Equivalents: 2011-2024

Historic Cash & Equivalents for Veracyte (VCYT) over the last 14 years, with Dec 2024 value amounting to $239.1 million.

  • Veracyte's Cash & Equivalents rose 15.14% to $315.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $315.6 million, marking a year-over-year increase of 15.14%. This contributed to the annual value of $239.1 million for FY2024, which is 10.46% up from last year.
  • Per Veracyte's latest filing, its Cash & Equivalents stood at $239.1 million for FY2024, which was up 10.46% from $216.5 million recorded in FY2023.
  • Veracyte's 5-year Cash & Equivalents high stood at $349.4 million for FY2020, and its period low was $154.2 million during FY2022.
  • Its 3-year average for Cash & Equivalents is $203.3 million, with a median of $216.5 million in 2023.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first skyrocketed by 119.29% in 2020, then slumped by 50.43% in 2021.
  • Yearly analysis of 5 years shows Veracyte's Cash & Equivalents stood at $349.4 million in 2020, then crashed by 50.43% to $173.2 million in 2021, then dropped by 10.94% to $154.2 million in 2022, then soared by 40.33% to $216.5 million in 2023, then rose by 10.46% to $239.1 million in 2024.